Acorda announces data of GGF2 preclinical studies for focal ischemic stroke Acorda Therapeutics.

Acorda is conducting preclinical stroke research with GGF2 further, and if the info continue to show promise, we plan to advance the substance to human medical trials in stroke, in addition to the presently planed trials in heart failure. Acorda plans to initiate Phase 1 studies in individuals with heart failure based on an Investigational New Drug application filed with the U.S. Food and Drug Administration in March 2010. The business can be pursuing preclinical research in additional cardiac and neurological applications for GGF2 and other neuregulin growth factors.. Acorda announces data of GGF2 preclinical studies for focal ischemic stroke Acorda Therapeutics, Inc, today announced that data from preclinical studies also show that Glial Growth Factor 2 promoted functional recovery following a permanent focal ischemic stroke.Ordinarily, these five cases would have eliminated undiagnosed. Related StoriesSausages With Antioxidants From Berries TO AVOID CancerResearchers find better genetic diversity among tumor cells than anticipatedNew results reveal association between colorectal cancer tumor and melanoma drug treatmentFurthermore, the 23 people with Lynch syndrome had 117 first-degree relatives who also may have inherited the mutations. The testing and counseling of these individuals revealed 52 people with undiagnosed Lynch syndrome; 65 of the people had no mutations. The method is less costly than the usual method of identifying MSI, a method referred to as genotyping, and it can be carried out by most hospital pathology laboratories.